Article Information
History
- October 12, 2021.
Article Versions
- Version 1 (October 6, 2021 - 23:43).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Wanda G.H. Han1,*,
- Arno Swart1,*,
- Axel Bonacic Marinovic1,
- Dirk Eggink1,
- Johan Reimerink1,
- Lisa A. Wijsman1,
- Bas van der Veer1,
- Sharon van den Brink1,
- Anne-Marie van den Brandt1,
- Sophie van Tol1,
- Gert-Jan Godeke1,
- Fion Brouwer1,
- Marieke Hoogerwerf1,
- On behalf of the Dutch FFX-COVID-19 research group,
- Daphne F.M. Reukers1,
- Nynke Rots1,
- Chantal Reusken1 and
- Adam Meijer1,†
- 1Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands
- ↵†Corresponding author contact information: Adam Meijer, Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveilance, Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM) PO Box 1, 3720 BA Bilthoven, the Netherlands, Tel.: +31 302743595, E-mail: Adam.Meijer{at}rivm.nl
↵* Equal contribution